Study #2014-0756
An Open Label, Multicenter, Phase Ib/II Study of BGB324 (Bemcentinib) Administered as a Single Agent or in Combination with Cytarabine or Decitabine in Patients with Acute Myeloid Leukemia or as a Single Agent in Patients with Myelodysplastic Syndrome
MD Anderson Study Status
Not Accepting
Treatment Agent
Bemcentinib, Cytarabine, Decitabine
Description
A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS) or in a combination with cytarabine or decitabine in AML participants. Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is overexpressed in up to half of AML cases.
Information and next steps
Disease:
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study phase:
I/II
Physician name:
Yesid Alvarado
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.